Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma
Identifieur interne : 000813 ( Pmc/Corpus ); précédent : 000812; suivant : 000814Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma
Auteurs : Chengcheng Hao ; Guiping Liu ; Guangliang TianSource :
- Therapeutic Advances in Respiratory Disease [ 1753-4658 ] ; 2019.
Abstract
Clinical treatment of non-small cell lung carcinoma (NSCLC) by cisplatin eventually results in drug resistance, which cancer stem cells and autophagy are believed to be involved in. In the present study, we aimed to explore the effect of autophagy-inhibited cancer stem cells in NSCLC.
Cancer stem cells were identified by CD133 expression levels detected by immunochemistry, real-time polymerase chain reaction, western blot, and flow cytometry. Stemness was detected by sphere-forming assays of tumor cells. Autophagy was determined by LC3-II expression at mRNA and protein levels. The effect of chloroquine (CQ) on autophagy was detected by real-time polymerase chain reaction, western blot and sphere-forming assay
Cisplatin (CDDP) treatment enhanced CD133+ cell ratios in clinical NSCLC specimens and NSCLC cell line A549. The CD133+ cells enriched by CDDP exhibited higher autophagy levels. Autophagy inhibition by CQ inhibited CD133+ stemness and promoted CDDP efficiency in A549 cells. In addition, the combination of CDDP and CQ treatment significantly inhibited autophagy levels and cancer stem cell proportions
Autophagy inhibition of cancer stem cells could promote the efficacy of cisplatin against NSCLC.
Url:
DOI: 10.1177/1753466619866097
PubMed: 31368411
PubMed Central: 6676261
Links to Exploration step
PMC:6676261Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma</title><author><name sortKey="Hao, Chengcheng" sort="Hao, Chengcheng" uniqKey="Hao C" first="Chengcheng" last="Hao">Chengcheng Hao</name></author><author><name sortKey="Liu, Guiping" sort="Liu, Guiping" uniqKey="Liu G" first="Guiping" last="Liu">Guiping Liu</name></author><author><name sortKey="Tian, Guangliang" sort="Tian, Guangliang" uniqKey="Tian G" first="Guangliang" last="Tian">Guangliang Tian</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31368411</idno><idno type="pmc">6676261</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676261</idno><idno type="RBID">PMC:6676261</idno><idno type="doi">10.1177/1753466619866097</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000813</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000813</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma</title><author><name sortKey="Hao, Chengcheng" sort="Hao, Chengcheng" uniqKey="Hao C" first="Chengcheng" last="Hao">Chengcheng Hao</name></author><author><name sortKey="Liu, Guiping" sort="Liu, Guiping" uniqKey="Liu G" first="Guiping" last="Liu">Guiping Liu</name></author><author><name sortKey="Tian, Guangliang" sort="Tian, Guangliang" uniqKey="Tian G" first="Guangliang" last="Tian">Guangliang Tian</name></author></analytic><series><title level="j">Therapeutic Advances in Respiratory Disease</title><idno type="ISSN">1753-4658</idno><idno type="eISSN">1753-4666</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="section1-1753466619866097"><title>Background:</title><p>Clinical treatment of non-small cell lung carcinoma (NSCLC) by cisplatin eventually results in drug resistance, which cancer stem cells and autophagy are believed to be involved in. In the present study, we aimed to explore the effect of autophagy-inhibited cancer stem cells in NSCLC.</p></sec><sec id="section2-1753466619866097"><title>Methods:</title><p>Cancer stem cells were identified by CD133 expression levels detected by immunochemistry, real-time polymerase chain reaction, western blot, and flow cytometry. Stemness was detected by sphere-forming assays of tumor cells. Autophagy was determined by LC3-II expression at mRNA and protein levels. The effect of chloroquine (CQ) on autophagy was detected by real-time polymerase chain reaction, western blot and sphere-forming assay <italic>in vitro</italic>, and tumor growth in male NOD/SCID mice.</p></sec><sec id="section3-1753466619866097"><title>Results:</title><p>Cisplatin (CDDP) treatment enhanced CD133<sup>+</sup> cell ratios in clinical NSCLC specimens and NSCLC cell line A549. The CD133<sup>+</sup> cells enriched by CDDP exhibited higher autophagy levels. Autophagy inhibition by CQ inhibited CD133<sup>+</sup> stemness and promoted CDDP efficiency in A549 cells. In addition, the combination of CDDP and CQ treatment significantly inhibited autophagy levels and cancer stem cell proportions <italic>in vitro</italic>, and dramatically suppressed tumor growth compared with individual agents.</p></sec><sec id="section4-1753466619866097"><title>Conclusion:</title><p>Autophagy inhibition of cancer stem cells could promote the efficacy of cisplatin against NSCLC.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Siegel, Rl" uniqKey="Siegel R">RL Siegel</name></author><author><name sortKey="Miller, Kd" uniqKey="Miller K">KD Miller</name></author><author><name sortKey="Jemal, A" uniqKey="Jemal A">A. Jemal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bray, F" uniqKey="Bray F">F Bray</name></author><author><name sortKey="Ferlay, J" uniqKey="Ferlay J">J Ferlay</name></author><author><name sortKey="Soerjomataram, I" uniqKey="Soerjomataram I">I Soerjomataram</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zappa, C" uniqKey="Zappa C">C Zappa</name></author><author><name sortKey="Mousa, Sa" uniqKey="Mousa S">SA. Mousa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Doroshow, Db" uniqKey="Doroshow D">DB Doroshow</name></author><author><name sortKey="Herbst, Rs" uniqKey="Herbst R">RS. Herbst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tilz, Gp" uniqKey="Tilz G">GP Tilz</name></author><author><name sortKey="Becker, H" uniqKey="Becker H">H. Becker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kelland, L" uniqKey="Kelland L">L. Kelland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schiller, Jh" uniqKey="Schiller J">JH Schiller</name></author><author><name sortKey="Harrington, D" uniqKey="Harrington D">D Harrington</name></author><author><name sortKey="Belani, Cp" uniqKey="Belani C">CP Belani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shackleton, M" uniqKey="Shackleton M">M Shackleton</name></author><author><name sortKey="Quintana, E" uniqKey="Quintana E">E Quintana</name></author><author><name sortKey="Fearon, Er" uniqKey="Fearon E">ER Fearon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Visvader, Je" uniqKey="Visvader J">JE Visvader</name></author><author><name sortKey="Lindeman, Gj" uniqKey="Lindeman G">GJ. Lindeman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gottschling, S" uniqKey="Gottschling S">S Gottschling</name></author><author><name sortKey="Schnabel, Pa" uniqKey="Schnabel P">PA Schnabel</name></author><author><name sortKey="Herth, Fj" uniqKey="Herth F">FJ Herth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sarvi, S" uniqKey="Sarvi S">S Sarvi</name></author><author><name sortKey="Mackinnon, Ac" uniqKey="Mackinnon A">AC Mackinnon</name></author><author><name sortKey="Avlonitis, N" uniqKey="Avlonitis N">N Avlonitis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akunuru, S" uniqKey="Akunuru S">S Akunuru</name></author><author><name sortKey="James Zhai, Q" uniqKey="James Zhai Q">Q James Zhai</name></author><author><name sortKey="Zheng, Y" uniqKey="Zheng Y">Y. Zheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Yp" uniqKey="Liu Y">YP Liu</name></author><author><name sortKey="Yang, Cj" uniqKey="Yang C">CJ Yang</name></author><author><name sortKey="Huang, Ms" uniqKey="Huang M">MS Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ma, S" uniqKey="Ma S">S Ma</name></author><author><name sortKey="Lee, Tk" uniqKey="Lee T">TK Lee</name></author><author><name sortKey="Zheng, Bj" uniqKey="Zheng B">BJ Zheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bertolini, G" uniqKey="Bertolini G">G Bertolini</name></author><author><name sortKey="Roz, L" uniqKey="Roz L">L Roz</name></author><author><name sortKey="Perego, P" uniqKey="Perego P">P Perego</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mizushima, N" uniqKey="Mizushima N">N Mizushima</name></author><author><name sortKey="Komatsu, M" uniqKey="Komatsu M">M. Komatsu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guo, Jy" uniqKey="Guo J">JY Guo</name></author><author><name sortKey="Xia, B" uniqKey="Xia B">B Xia</name></author><author><name sortKey="White, E" uniqKey="White E">E. White</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Wu, Gs" uniqKey="Wu G">GS. Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, S" uniqKey="Chen S">S Chen</name></author><author><name sortKey="Rehman, Sk" uniqKey="Rehman S">SK Rehman</name></author><author><name sortKey="Zhang, W" uniqKey="Zhang W">W Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dean, M" uniqKey="Dean M">M Dean</name></author><author><name sortKey="Fojo, T" uniqKey="Fojo T">T Fojo</name></author><author><name sortKey="Bates, S" uniqKey="Bates S">S. Bates</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeppernick, F" uniqKey="Zeppernick F">F Zeppernick</name></author><author><name sortKey="Ahmadi, R" uniqKey="Ahmadi R">R Ahmadi</name></author><author><name sortKey="Campos, B" uniqKey="Campos B">B Campos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mizushima, N" uniqKey="Mizushima N">N. Mizushima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robert, T" uniqKey="Robert T">T Robert</name></author><author><name sortKey="Vanoli, F" uniqKey="Vanoli F">F Vanoli</name></author><author><name sortKey="Chiolo, I" uniqKey="Chiolo I">I Chiolo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mizushima, N" uniqKey="Mizushima N">N Mizushima</name></author><author><name sortKey="Levine, B" uniqKey="Levine B">B Levine</name></author><author><name sortKey="Cuervo, Am" uniqKey="Cuervo A">AM Cuervo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munoz Gamez, Ja" uniqKey="Munoz Gamez J">JA Munoz-Gamez</name></author><author><name sortKey="Rodriguez Vargas, Jm" uniqKey="Rodriguez Vargas J">JM Rodriguez-Vargas</name></author><author><name sortKey="Quiles Perez, R" uniqKey="Quiles Perez R">R Quiles-Perez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Degenhardt, K" uniqKey="Degenhardt K">K Degenhardt</name></author><author><name sortKey="Mathew, R" uniqKey="Mathew R">R Mathew</name></author><author><name sortKey="Beaudoin, B" uniqKey="Beaudoin B">B Beaudoin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kang, R" uniqKey="Kang R">R Kang</name></author><author><name sortKey="Tang, D" uniqKey="Tang D">D Tang</name></author><author><name sortKey="Schapiro, Ne" uniqKey="Schapiro N">NE Schapiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huo, Y" uniqKey="Huo Y">Y Huo</name></author><author><name sortKey="Cai, H" uniqKey="Cai H">H Cai</name></author><author><name sortKey="Teplova, I" uniqKey="Teplova I">I Teplova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carew, Js" uniqKey="Carew J">JS Carew</name></author><author><name sortKey="Nawrocki, St" uniqKey="Nawrocki S">ST Nawrocki</name></author><author><name sortKey="Kahue, Cn" uniqKey="Kahue C">CN Kahue</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="publisher-id">TAR</journal-id><journal-id journal-id-type="hwp">sptar</journal-id><journal-title-group><journal-title>Therapeutic Advances in Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1753-4658</issn><issn pub-type="epub">1753-4666</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31368411</article-id><article-id pub-id-type="pmc">6676261</article-id><article-id pub-id-type="doi">10.1177/1753466619866097</article-id><article-id pub-id-type="publisher-id">10.1177_1753466619866097</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Chengcheng</given-names></name><aff id="aff1-1753466619866097">Department of Radiation Oncology, Liaocheng People’s Hospital, Liaocheng, Shandong, China</aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Guiping</given-names></name><aff id="aff2-1753466619866097">Department of Radiation Oncology, Liaocheng People’s Hospital, Liaocheng, Shandong, China</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9464-8307</contrib-id><name><surname>Tian</surname><given-names>Guangliang</given-names></name><xref ref-type="corresp" rid="corresp1-1753466619866097"></xref><aff id="aff3-1753466619866097">Department of Radiation Oncology, Liaocheng Cancer Hospital, No 45 Jianshe East Road, Liaocheng, Shandong, 252000, China</aff></contrib></contrib-group><author-notes><corresp id="corresp1-1753466619866097"><email>tglly1980@163.com</email></corresp><fn fn-type="other"><p>The reviews of this paper are available via the supplemental material section.</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>8</month><year>2019</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2019</year></pub-date><volume>13</volume><elocation-id>1753466619866097</elocation-id><history><date date-type="received"><day>5</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s), 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-1753466619866097"><title>Background:</title><p>Clinical treatment of non-small cell lung carcinoma (NSCLC) by cisplatin eventually results in drug resistance, which cancer stem cells and autophagy are believed to be involved in. In the present study, we aimed to explore the effect of autophagy-inhibited cancer stem cells in NSCLC.</p></sec><sec id="section2-1753466619866097"><title>Methods:</title><p>Cancer stem cells were identified by CD133 expression levels detected by immunochemistry, real-time polymerase chain reaction, western blot, and flow cytometry. Stemness was detected by sphere-forming assays of tumor cells. Autophagy was determined by LC3-II expression at mRNA and protein levels. The effect of chloroquine (CQ) on autophagy was detected by real-time polymerase chain reaction, western blot and sphere-forming assay <italic>in vitro</italic>, and tumor growth in male NOD/SCID mice.</p></sec><sec id="section3-1753466619866097"><title>Results:</title><p>Cisplatin (CDDP) treatment enhanced CD133<sup>+</sup> cell ratios in clinical NSCLC specimens and NSCLC cell line A549. The CD133<sup>+</sup> cells enriched by CDDP exhibited higher autophagy levels. Autophagy inhibition by CQ inhibited CD133<sup>+</sup> stemness and promoted CDDP efficiency in A549 cells. In addition, the combination of CDDP and CQ treatment significantly inhibited autophagy levels and cancer stem cell proportions <italic>in vitro</italic>, and dramatically suppressed tumor growth compared with individual agents.</p></sec><sec id="section4-1753466619866097"><title>Conclusion:</title><p>Autophagy inhibition of cancer stem cells could promote the efficacy of cisplatin against NSCLC.</p></sec></abstract><kwd-group><kwd>autophagy</kwd><kwd>cancer stem cell</kwd><kwd>cisplatin</kwd><kwd>non-small cell lung carcinoma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-1753466619866097"><title>Introduction</title><p>Lung cancer remains the most common cancer worldwide, and is the most common cause of cancer-related death.<sup><xref rid="bibr1-1753466619866097" ref-type="bibr">1</xref>,<xref rid="bibr2-1753466619866097" ref-type="bibr">2</xref></sup> Patients with lung cancer display poor prognosis with less than 20% of 5-year overall survival.<sup><xref rid="bibr3-1753466619866097" ref-type="bibr">3</xref></sup> More than 50% of all lung cancers are non-small cell lung carcinoma (NSCLC), which accounts for the most common subtype.<sup><xref rid="bibr4-1753466619866097" ref-type="bibr">4</xref>,<xref rid="bibr5-1753466619866097" ref-type="bibr">5</xref></sup> In the clinic, strategies for NSCLC treatment range from traditional surgery, radiation, chemotherapy to novel targeted therapy; however, the effect of various treatments is limited. More importantly, approximately 40% of patients with NSCLC are at a late stage on diagnosis.<sup><xref rid="bibr3-1753466619866097" ref-type="bibr">3</xref></sup> Platinum-based chemotherapy was mostly accepted for advanced NSCLC treatment,<sup><xref rid="bibr6-1753466619866097" ref-type="bibr">6</xref>,<xref rid="bibr7-1753466619866097" ref-type="bibr">7</xref></sup> but the efficacy of chemotherapy is suppressed by increased drug resistance. Therefore, exploration of the mechanism of chemotherapy resistance and consequently increasing the efficiency of platinum-based chemotherapy to patients with NSCLC are urgently needed.</p><p>Accumulating evidence illustrated that cancer stem cells represent a crucial factor in platinum-based chemotherapy, owing to the properties of self-renewal, differentiation, high tumorigenicity and drug resistance.<sup><xref rid="bibr8-1753466619866097" ref-type="bibr">8</xref><xref rid="bibr9-1753466619866097" ref-type="bibr"></xref><xref rid="bibr10-1753466619866097" ref-type="bibr"></xref><xref rid="bibr11-1753466619866097" ref-type="bibr"></xref>–<xref rid="bibr12-1753466619866097" ref-type="bibr">12</xref></sup> Chemotherapy successfully decreases tumor burden <italic>via</italic> the killing of fast-proliferating tumor cells; however, it remains ineffective at eliminating cancer stem cells. More importantly, chemotherapy could even lead to an enrichment of cancer stem cells.<sup><xref rid="bibr13-1753466619866097" ref-type="bibr">13</xref><xref rid="bibr14-1753466619866097" ref-type="bibr"></xref>–<xref rid="bibr15-1753466619866097" ref-type="bibr">15</xref></sup></p><p>Autophagy is defined as the process of intracellular degradation of cytoplasmic materials in the lysosome and is the dynamic recycling system that provides the energy and necessary materials for cellular regeneration.<sup><xref rid="bibr16-1753466619866097" ref-type="bibr">16</xref></sup> The correlation between autophagy, tumorigenesis and drug resistance has been widely investigated. Autophagy supplies metabolic substrates essential for cancer cell survival that support tumor growth.<sup><xref rid="bibr17-1753466619866097" ref-type="bibr">17</xref></sup> Moreover, elevated autophagy levels enhance the drug resistance of cancer cells.<sup><xref rid="bibr18-1753466619866097" ref-type="bibr">18</xref>,<xref rid="bibr19-1753466619866097" ref-type="bibr">19</xref></sup> In the present study, we aimed to explore the effect of autophagy inhibition of cancer stem cells in the cisplatin (CDDP)-based drug resistance of NSCLC. Cisplatin treatment enriched CD133<sup>+</sup> cancer stem cells with a high autophagy level. Autophagy inhibition by chloroquine (CQ) dramatically suppressed the proportion and stemness of cancer stem cells, and increased the sensitivity of tumor cells to CDDP treatment. In mouse models, autophagy inhibition repressed tumor growth by decreasing the percentage of cancer stem cells.</p></sec><sec sec-type="methods" id="section6-1753466619866097"><title>Methods</title><sec id="section7-1753466619866097"><title>Human samples and cell line</title><p>A total of 10 human NSCLC samples (5 before cisplatin treatment and 5 after cisplatin treatment) were collected in Liaocheng Cancer Hospital, China, between 2015 and 2017. The 10 tissues were collected by endobronchial biopsy, and further confirmed as NSCLC by a histologist. For CD133 immunochemistry, the tissues were fixed in formalin, paraffin-embedded and sectioned in 5 μm thickness. Written consents regarding the tumor samples used for this study were obtained before the experiments. The study was conducted according to the World Medical Association Declaration of Helsinki, and was approved by the ethics committees of Liaocheng Cancer Hospital (#2015LCHJW038). The human NSCLC cell line A549 was purchased from the Cell Bank of Shanghai, China. A549 cells were cultured in Roswell Park Memorial Institute (RPMI) medium 1640 (Gibco, Grand Island, NY) supplied with 10% fetal bovine serum (FBS; Gibco) in a humidified incubator with 5% (v/v) CO<sub>2</sub>.</p></sec><sec id="section8-1753466619866097"><title>Real-time polymerase chain reaction</title><p>RNAs from tumor tissues and cell lines were isolated using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Then, cDNA was synthesized using Prime-Script RT Kit (Takara, Dalian, China). The mRNA expression levels of CD133, Sox2, Oct4, Nanog and ABCG2 was determined by real-time polymerase chain reaction. The primers used were as follows: CD133: F 5′ GCC ACC GCT CTA GAT ACT GC3′, 5′GCT TTT CCT ATG CCA AAC CA3′; Sox2: F 5′CAT GTC CCA GCA CTA CCA GA3′, R 5′ ATG TGT GAG AGG GGC AGT GT3′; Sox4, F 5′AGT GAG AGG CAA CCT GGA GA3′, R 5′ ACA CTC GGA CCA CAT CCT TC3′; Nanog, F 5′ AAC TGG CCG AAG AAT AGC AA3′, R 5′ CAT CCC TGG TGG TAG GAA GA3′; ABCG2, F 5′ATG GAT TTA CGG CTT TGC AG3′, R 5′ TGA GTC CTG GGC AGA AGT TT3′. The relative mRNA levels were detected by the 2<sup>−ΔΔCt</sup> method. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression level was used for normalization.</p></sec><sec id="section9-1753466619866097"><title>Western blot</title><p>Tissues or cells were lysed by radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher, Waltham, MA) supplied with protease inhibitor cocktail (Abcam). The lysates were quantified by a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher). Then, a total of 10 µg proteins were loaded into 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), followed by transferring onto an immobilon transfer membrane (Millipore, Billerica, MA). The membranes were incubated with primary antibodies of CD133 (Cell Signaling Technology, Danvers, MA, 5860s, 1:1,000), LC3 (Novus Biologicals, Shanghai, China, NB100–2220, 1:2,000), p62 (Abcam, ab194721, 1:1000), b-actin (Novus Biologicals, NB600-501, 1:1,000) and GAPDH (Chemicon, Billerica, MA, AB9132, 1:10,000) at 4°C overnight. Then, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Technology). Signals were detected by a chemiluminescence reaction. The signal intensities were quantified using the software, ImageJ (version 1.47, NIH, Bethesda, MD).</p></sec><sec id="section10-1753466619866097"><title>MTT assay</title><p>Cell viability was detected by MTT assay. A total of 5,000 cells were seeded into 96-well plates, following culture for 24 h. Then, different doses of CDDP (0, 20, 40, 60, 80, 100 µM) were added into wells and incubated for 48 h. Finally, cell viability was detected using an MTT kit (Thermo Fisher Scientific, V13154, Waltham, MA, USA) according to the manufacturer’s protocol. Briefly, 3–5 × 10<sup>4</sup> cells/well were cultured in 96-well plates for 48 h. At the end of culture, 50 μl of the MTT reagent (5 mg/ml) was added to each well and incubated for 4 h, followed by adding 200 μl of dimethyl sulfoxide to each well and incubating for 15 mins. The absorbance was read using a microplate reader (SpectraMAX Plus, Molecular Devices, Sunnyvale, CA, USA) at a wavelength of 570 nm.</p></sec><sec id="section11-1753466619866097"><title>Immunohistochemistry</title><p>Paraffin sections in 5 μm thickness were deparaffinated and rehydrated. Then, 3% H<sub>2</sub>O<sub>2</sub> in methanol was used to quench endogenous peroxidase activity at room temperature for 30 mins, followed by incubation with 10% bovine serum albumin at room temperature for 60 mins. The sections were then incubated with primary antibodies of CD133 (Cell Signaling Technology, 5860s, 1:1,000) or PCNA (Cell Signaling Technology, 13110S, 1:1,000) at 4°C overnight. The positive immune signals were visualized by an envision and peroxidase system. Then, DAB-chromogen (Biocare Medical, SKU: DB801) was carried out according to the manufacturer’s procedures.</p></sec><sec id="section12-1753466619866097"><title>Immunofluorescence</title><p>For tissues: tissues were fixed by 4% paraformaldehyde (Sigma, St. Louis, MO, 30525-89-4), followed by embedding in paraffin. The paraffin sections in 5 μm thickness were deparaffinized and rehydrated, followed by incubation with Alexa Fluor<sup>®</sup> 647-conjunted p62 primary antibody (Abcam, ab194721, 1:1,000). DAPI (4′,6-diamidino-2-phenylindole) was used for nuclear staining. The signals were detected using confocal microscopy.</p><p>For GFP-LC3-A549 cells: GFP-LC3-A549 cells were transfected with GFP-LC3pcDNA3.1/hygro (+) plasmid (Invitrogen, Waltham, MA, USA) using lipofectamine 2000 (Thermo Fisher Scientific, 11668019) following the manufacturer’s procedures. Then, the cells were fixed in sections and the signals were detected using confocal microscopy.</p></sec><sec id="section13-1753466619866097"><title>Colony-forming assay and sphere-forming assay</title><p>For colony-forming assays, a total of 500 cells were seeded onto six-well plate and cultured in RPMI 1640 medium (Gibco, Grand Island, NY) supplied with 10% FBS (Gibco) for 10 days. Then, colony formation was visualized by purple crystal staining. For the sphere-forming assay, a total of 100 cells were seeded onto a low adhesion six-well plate containing Dulbecco’s modified Eagle’s medium (DMEM)/F-12 with N2 supplement (Invitrogen, Grand Island, NY), 20 ng/ml epidermal growth factor (EGF), and 20 ng/ml basic fibroblast growth factor (PeproTech, Rocky Hill, CT) and referred to stem cell medium for 10 days. Then, sphere formation was detected and photographed using microscopy.</p></sec><sec id="section14-1753466619866097"><title>Flow cytometry</title><p>Single cell suspensions of A549 cells or those dissociated from tumor tissues were used for flow cytometry analysis. A total of 1 × 10<sup>6</sup> cells from each sample were stained with CD133-PE (phycoerythrin) antibody (BD Biosciences, Franklin Lakes, NJ, 566593, clone W6B3C1) at a dose of 1 µl/200 µl phosphate-buffered saline (PBS) for 15 mins at 4°C. Then, cells were washed with cold PBS and flow cytometric analysis was performed using FACS Calibur (BD Biosciences).</p></sec><sec id="section15-1753466619866097"><title><italic>In vivo</italic> xenograft model</title><p>A total of 3 × 10<sup>6</sup> A549 cells were subcutaneously injected into the right flanks of male NOD/SCID mice aged 6–8 weeks and weighing 17.8–24.1 g. Mice were purchased from Beijing Vital River Company (Beijing, China). A total of four mice were housed per cage with free access to food and water at 22–25°C with humidity of 50 ± 2%. A total of 168 mice were randomly divided into four groups: PBS, CDDP, CQ and CDDP + CQ, and were treated every 3 days five times when the tumor volume was 50 mm<sup>3</sup>. The administration dosage of CDDP and CQ were 2.5 mg/kg intravenously (i.v.) and 10.0 mg/kg (i.v.), respectively. The tumor volumes of different groups were measured every 3 days after implantation using the formula: length × width<sup><xref rid="bibr2-1753466619866097" ref-type="bibr">2</xref></sup> × 0.5. At 21 days after implantation, the mice were euthanized by carbon monoxide and the tumors weighed. The protocols for animal experiments were in accordance with the Guide for the Care and Use of Laboratory Animals published by National Institutes of Health. Animal study was with the oversight of the animal facility in Liaocheng People’s Hospital, and was reviewed and approved by the Ethics Committee of Liaocheng People’s Hospital (#LPH-5P36).</p></sec><sec id="section16-1753466619866097"><title>Statistical analysis</title><p>All data were detected as the mean ± standard deviation (SD) from at least three separate experiments. The levels of significance were: <sup>*</sup><italic>p</italic> < 0.05, <sup>**</sup><italic>p</italic> < 0.005 and <sup>***</sup><italic>p</italic> < 0.001. A Student’s <italic>t</italic>-test or analysis of variance was used to determine statistical significance. In all cases, <italic>p</italic> < 0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="section17-1753466619866097"><title>Results</title><sec id="section18-1753466619866097"><title>CDDP treatment enhanced CD133<sup>+</sup> cancer stem cells</title><p>Cancer stem cells were believed to be closely involved in drug resistance,<sup><xref rid="bibr20-1753466619866097" ref-type="bibr">20</xref></sup> which promoted us to determine cancer stem cell alteration after CDDP treatment. CD133 was commonly used as a cancer stem cell marker.<sup><xref rid="bibr21-1753466619866097" ref-type="bibr">21</xref></sup> As shown in <xref ref-type="fig" rid="fig1-1753466619866097">Figure 1(a)</xref>, enhanced CD133 staining by immunochemistry was observed in clinical NSCLC samples after CDDP treatment. The percentage of CD133<sup>+</sup> cells in the high-power field dramatically increased after CDDP treatment (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1753466619866097">Figure S1</ext-link>). Consistently, CD133 mRNA and protein levels were dramatically upregulated in CDDP-treated clinical NSCLC samples [<xref ref-type="fig" rid="fig1-1753466619866097">Figure 1(b)</xref>].</p><fig id="fig1-1753466619866097" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>CDDP treatment elevates the ratio of CD133<sup>+</sup> cells within specimens and cell line of NSCLC. (a) Representative images showed the immunohistochemistry of CD133 staining in the clinical specimens before and post CDDP treatment from patient with NSCLC. Scale bar, 20 μm. (b) mRNA and protein level of CD133 in the clinical specimens before and post CDDP treatment from patients with NSCLC. Data represent means ± SD. <sup>**</sup><italic>p</italic> < 0.005, <italic>n</italic> = 6. (c) A549 cells were treated with different concentrations of CDDP for 48 h. The cell viability was determined by an MTT assay. (d) Percentages of CD133<sup>+</sup> CSCs in A549 cells with or without the treatment of low dose of cisplatin for 48 h, respectively. The CDDP concentration was IC<sub>20</sub>, about 2.5 μM. CSCs were stained with anti-CD133-PE antibody and analyzed by flow cytometer. Data are shown as mean ± SD (<italic>n</italic> = 6). (e) mRNA levels of ‘stemness’-associated genes in A549 cells after CDDP treatment. A549 cells were treated with 2.5 μM CDDP for 48 h. The mRNA levels of ‘stemness’-associated genes were analyzed by qPCR, the mRNA levels of genes were normalized against the expression level of housekeeping gene GAPDH, <sup>*</sup><italic>p</italic> < 0.05, <sup>**</sup><italic>p</italic> < 0.005, <sup>***</sup><italic>p</italic> < 0.001, <italic>n</italic> = 6. (f) CDDP-treated A549 cells were subjected to the tumor sphere-forming assay. Scale bar, 100 μm.</p><p>CDDP, cisplatin; CSC, cancer stem cell; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NSCLC, non-small cell lung cancer; qPCR, quantitative polymerase chain reaction; SD, standard deviation.</p></caption><graphic xlink:href="10.1177_1753466619866097-fig1"></graphic></fig><p>The effect of CDDP in NSCLC cell line A549 was also assessed. CDDP inhibited cell viability of A549 in a dose-dependent manner [<xref ref-type="fig" rid="fig1-1753466619866097">Figure 1(c)</xref>]. Consistent with the clinical results, CDDP treatment greatly enhanced the CD133<sup>+</sup> cancer stem cell proportion in the A549 cell line [<xref ref-type="fig" rid="fig1-1753466619866097">Figure 1(d)</xref>]. To further confirm the effect of CDDP in cancer stem cells, the expression levels of stemness-associated genes were determined by RT-PCR. As shown in <xref ref-type="fig" rid="fig1-1753466619866097">Figure 1(e)</xref>, CDDP treatment significantly enhanced the selected stemness-associated gene (<italic>Sox2, Oct4, Nanog</italic> and <italic>ABCG2</italic>) expression levels. In addition, the tumor sphere formation ability of A549 cells was greatly improved after CDDP treatment [<xref ref-type="fig" rid="fig1-1753466619866097">Figure 1(f)</xref>]. These results demonstrated that CDDP treatment enhanced CD133<sup>+</sup> cancer stem cells.</p></sec><sec id="section19-1753466619866097"><title>CD133<sup>+</sup> cancer stem cells exhibit higher autophagy levels</title><p>Accumulating reports indicated the correlation of autophagy with drug resistance.<sup><xref rid="bibr19-1753466619866097" ref-type="bibr">19</xref></sup> Therefore, we inspected autophagy levels of CDDP-enriched CD133<sup>+</sup> cancer stem cells. Enrichment of CD133<sup>+</sup> cells was first confirmed by flow cytometry and western blot [<xref ref-type="fig" rid="fig2-1753466619866097">Figure 2(a)</xref>]. Comparing with CD133<sup>–</sup> cells, CD133<sup>+</sup> exhibited much higher LC3-II protein levels [<xref ref-type="fig" rid="fig2-1753466619866097">Figure 2(b)</xref>], which is commonly used as an autophagy marker.<sup><xref rid="bibr22-1753466619866097" ref-type="bibr">22</xref></sup> Enhanced autophagy levels in CD133<sup>+</sup> were further verified by fluorescence of EGFP-LC3 in A549 cells [<xref ref-type="fig" rid="fig2-1753466619866097">Figure 2(c)</xref>]. These results indicated that CDDP-enriched CD133<sup>+</sup> cancer stem cells exhibit higher autophagy levels.</p><fig id="fig2-1753466619866097" orientation="portrait" position="float"><label>Figure 2.</label><caption><p><bold>CDDP-enriched CD133</bold><sup>+</sup><bold>cancer stem cells exhibit enhanced levels of autophagy.</bold> (a) CD133 and CD133<sup>+</sup> cells were sorted from A549 cells were treated with 2.5 μM CDDP for 48 h. The purities of CD133<sup>–</sup> and CD133<sup>+</sup> cells were evaluated by flow cytometry and western blotting. (b) Western blotting and densitometric analysis of LC3-II levels in CD133 and CD133<sup>+</sup> A549 cells. GAPDH was used as a loading control. The signal intensities were quantified using software ImageJ (version 1.47) (<italic>n</italic> = 6). (c) Fluorescent microscopy images of CD133 and CD133<sup>+</sup> EGFP-LC3/A549 cells. Bright punctate dots indicated the induction of autophagy. Scale bar, 10 µm.</p><p>CDDP, cisplatin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.</p></caption><graphic xlink:href="10.1177_1753466619866097-fig2"></graphic></fig></sec><sec id="section20-1753466619866097"><title>Autophagy inhibition suppressed stemness of CD133<sup>+</sup> cells and enhanced CDDP efficiency in A549 cells</title><p>Results shown in <xref ref-type="fig" rid="fig2-1753466619866097">Figure 2</xref> demonstrated higher autophagy levels in CD133<sup>+</sup> cancer stem cells, which caused us to explore the influence of the autophagy inhibitor chloroquine (CQ) on the biological functions of CD133<sup>+</sup> cancer stem cells. The effect of CQ in inhibiting autophagy was affirmed by western blot, as CQ administration elevated LC3-II and p62 expression levels in a dose-dependent manner [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(a)</xref>]. Meanwhile, the proportion of CD133<sup>+</sup> cells was dramatically suppressed after CQ treatment [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(b)</xref>]. CQ administration significantly inhibited CD133<sup>+</sup> cell viability of CD133<sup>−</sup> and CD133<sup>+</sup> cells [<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1753466619866097">Figure S2(a and b)</ext-link>]. In addition, colony formation was much less in CQ-treated CD133<sup>+</sup> cells [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(c)</xref>]. Decreased stemness of CD133<sup>+</sup> cancer stem cells indicated by sphere-forming assay was observed after CQ treatment [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(d)</xref>].</p><fig id="fig3-1753466619866097" orientation="portrait" position="float"><label>Figure 3.</label><caption><p><bold>CQ-mediated inhibition of autophagy reduces the ‘stemness’ of CD133</bold><sup>+</sup><bold>A549 cells and promotes efficiency of CDDP in A549 cells.</bold> (a) Protein expression of LC3 and p62 in CD133<sup>+</sup> A549 cells after incubation with different concentration of CQ for 48 h and densitometric analysis, GAPDH was used as a loading control. The signal intensities were quantified using software ImageJ (version 1.47) (<italic>n</italic> = 6). (b) The proportion of CD133<sup>+</sup> A549 cells in sorted cells after treatment with CQ (10 μM) for 48 h. Data represent means ± SD. <sup>**</sup><italic>p</italic> < 0.005, <italic>n</italic> = 6. (c) CQ-treated sorted CD133<sup>+</sup> A549 cells were subjected to the colony-forming assay. (d) CQ-treated sorted CD133<sup>+</sup> A549 cells were subjected to sphere-forming assay. Scale bar, 100 μm. (e) Percentage of CD133<sup>+</sup> cells in A549 cells after co-incubation with CDDP and CQ for 48 h, the concentrations of CDDP and CQ were 2.5 μM and 10 μM, respectively. Data represent means ± SD. <sup>**</sup><italic>p</italic> < 0.005, <italic>n</italic> = 6. (f) The ability of A549 cells to regenerate spheres. A549 cells were treated with CDDP and CQ for 48 h, and then cells were seeded onto a six-well ultra-low attachment plate with complete spheres medium (100 cells per well). After 10 days, the number of newly formed spheres per well was determined under the microscope. Data represent means ± SD. <sup>**</sup><italic>p</italic> < 0.005, (CDDP + CQ <italic>versus</italic> CDDP), <italic>n</italic> = 6. (g) MTT analyses of the viability of A549 cell after treatment with CDDP, CQ or a combination for 48 h. Cell viability was normalized to that of PBS-treated cells which served as the indicator of 100% cell viability. Data represent means ± SD. <sup>**</sup><italic>p</italic> < 0.005 (CDDP + CQ <italic>versus</italic> CDDP), <italic>n</italic> = 6. The concentrations of CDDP and CQ were 2.5 μM and 10 μM, respectively.</p><p>CDDP, cisplatin; CQ, chloroquine; PBS, phosphate-buffered saline; SD, standard deviation.</p></caption><graphic xlink:href="10.1177_1753466619866097-fig3"></graphic></fig><p>The effect of autophagy inhibition on CDDP efficiency in A549 cells was further evaluated. Combined administration of CDDP and CQ greatly enhanced the ability of CDDP to decrease CD133<sup>+</sup> cancer stem cells [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(e)</xref>], suppress sphere formation [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(f)</xref>] and cell viability [<xref ref-type="fig" rid="fig3-1753466619866097">Figure 3(g)</xref>] of A549 cells, suggested that CQ administration improved the efficiency of CDDP in A549 cells.</p></sec><sec id="section21-1753466619866097"><title>Autophagy inhibition elevated CDDP efficiency in tumor growth</title><p>Next, we explored the effect of CQ-mediated autophagy inhibition in tumor growth after CDDP treatment. Subcutaneous A549 tumors were first established. Individual CDDP or CQ treatment displayed a trend of inhibiting tumor growth, but without significance. The combination of CDDP and CQ significantly suppressed tumor growth [<xref ref-type="fig" rid="fig4-1753466619866097">Figure 4(a)</xref>]. In addition, the tumor weight in the CDDP + CQ group was much lower than the CDDP group [<xref ref-type="fig" rid="fig4-1753466619866097">Figure 4(b)</xref>].</p><fig id="fig4-1753466619866097" orientation="portrait" position="float"><label>Figure 4.</label><caption><p><bold><italic>In vivo</italic> anti-tumor effect of CDDP, CQ and a combination of two agents.</bold> (a) Inhibition of tumor growth by various treatments in A549 tumor-bearing NOD/SCID mice (<italic>n</italic> = 6). Male NOD/SCID mice bearing A549 tumors of ~50 mm<sup>3</sup> received PBS, CDDP, CQ or combination of CDDP and CQ every 3 days five times, the administration dosage of CDDP and CQ were 2.5 mg/kg (i.v.) and 10.0 mg/kg (i.v.), respectively. <sup>**</sup><italic>p</italic> < 0.005, <sup>***</sup><italic>p</italic> < 0.001 (<italic>versus</italic> CDDP group). (b) Tumor weights of different groups at the end of treatments. <sup>***</sup><italic>p</italic> < 0.001 (<italic>versus</italic> CDDP group); (c) PCNA analysis (immunohistochemistry) and TUNEL analysis (immunofluorescence) of tumor tissues after treatment with various therapeutic agents. The PCNA-positive proliferating cells are stained brown, TUNEL-positive cells are green. Scale bar was 20 μm.</p><p>CDDP, cisplatin; CQ, chloroquine; i.v., intravenously; PBS, phosphate-buffered saline; PCNA, Proliferating cell nuclear antigen; SD, standard deviation; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.</p></caption><graphic xlink:href="10.1177_1753466619866097-fig4"></graphic></fig><p>We further detected in detail what happened in tumors after different treatments. Combination treatments dramatically suppressed tumor cell proliferation, which was indicated by immunochemistry of PCNA [<xref ref-type="fig" rid="fig4-1753466619866097">Figure 4(c)</xref>]. Meanwhile, increased terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells demonstrated that the combination treatment enhanced tumor cell apoptosis [<xref ref-type="fig" rid="fig4-1753466619866097">Figure 4(c)</xref>]. These results indicate that CQ-mediated autophagy inhibition elevated CDDP efficiency in tumor growth at least partially <italic>via</italic> inhibiting tumor cell proliferation or promoting tumor cell apoptosis.</p></sec><sec id="section22-1753466619866097"><title>Combination therapy inhibits autophagy and suppresses cancer stem cell subpopulation <italic>in vivo</italic></title><p>We next detected alteration of autophagy and cancer stem cells in tumor tissues after different treatments. A combination of CDDP with CQ greatly inhibited autophagy compared with CDDP or CQ alone, as evidenced by increased LC3-II expression levels [<xref ref-type="fig" rid="fig5-1753466619866097">Figure 5(a)</xref>]. Immunofluorescence of the p62 protein further confirmed the decreased autophagy levels after combination therapy [<xref ref-type="fig" rid="fig5-1753466619866097">Figure 5(b)</xref>]. More importantly, combination therapy dramatically suppressed the percentage of CD133<sup>+</sup> cancer stem cells, which was elevated by CDDP treatment [<xref ref-type="fig" rid="fig5-1753466619866097">Figure 5(c</xref> and <xref ref-type="fig" rid="fig5-1753466619866097">d</xref>)]. Consistently, the mRNA expression levels of stemness markers, such as Sox2, Oct4, Nanog, ABCG2 and CD133 were significantly inhibited by CDDP and the CQ combination treatment [<xref ref-type="fig" rid="fig5-1753466619866097">Figure 5(e)</xref>].</p><fig id="fig5-1753466619866097" orientation="portrait" position="float"><label>Figure 5.</label><caption><p><bold>Combination therapy inhibits autophagy and suppresses CSC subpopulation <italic>in vivo</italic>.</bold> (a) Protein expressions of LC3-I and LC3-II in tumor tissues after treatment with CDDP, CQ or a combination of two agents. GAPDH was used as a loading control. (b) The immunofluorescence of p62 protein in tumor cells after treatment with various agents. The nuclei were stained with DAPI (blue), p62 protein was stained with anti-p62 antibody labeled with Alexa Fluor 647. (c) Xenografted tumor at the end of therapy were dissociated into single cells and stained with anti-CD133 labeled with PE for flow cytometry analysis. (d) Quantitative analysis of CD133<sup>+</sup> cells in tumor tissues. CDDP treatment significantly increase CD133<sup>+</sup> cells and cotreatment of autophagy inhibitor CQ blocked the induction effect of CDDP on the percentage of CD133<sup>+</sup> cells. Data represent means ± SD. <italic>n</italic> = 6, <sup>**</sup><italic>p</italic> < 0.005. (e) mRNA expression levels of stemness-associated genes (including Sox2, Oct4, Nanog, ABCG2 and CD133) in A549 tumor tissue at the end-point of treatment.</p><p>CDDP, Cisplatin; DAPI, 4′,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PE, phycoerythrin.</p></caption><graphic xlink:href="10.1177_1753466619866097-fig5"></graphic></fig><p>To further confirm the effect of autophagy inhibition on cancer stem cells, we performed a knockdown of <italic>ATG5</italic> (a key autophagy gene) using shRNA in A549 cell lines [<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1753466619866097">Figure S3(a)</ext-link>]. <italic>ATG5</italic> downregulation counteracts the increase in CD133<sup>+</sup> cells induced by CDDP [<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1753466619866097">Figure S3(b)</ext-link>]. These results demonstrated that a combination of CDDP and autophagy inhibition suppresses cancer stem cell subpopulation <italic>in vivo.</italic></p></sec></sec><sec sec-type="discussion" id="section23-1753466619866097"><title>Discussion</title><p>NSCLC is a major type of lung cancer that is the most common cancer worldwide and is great threat for public health. CDDP was commonly used for NSCLC treatment, while drug resistance remains as the crucial challenge for CDDP-based chemotherapy of NSCLC treatment. Cancer stem cells were believed to be associated with drug resistance. In human and mouse small cell lung cancer (SCLC), CD133 expression levels increased after chemotherapy. Notably, CD133<sup>+</sup> cancer stem cells showed increased tumorigenicity with higher Akt/PKB and Bcl-2 expression levels.<sup><xref rid="bibr11-1753466619866097" ref-type="bibr">11</xref></sup> The results prompted us to explore the effect of cancer stem cells in CDDP-based chemotherapy of NSCLC treatment. In the present study, we found that in clinical NSCLC samples, CD133<sup>+</sup> cancer stem cells were enriched after CDDP treatment, as evidenced by elevated immunochemistry of CD133, enhanced CD133 expression levels at both mRNA and protein levels. The increased proportion of CD133<sup>+</sup> cells after CDDP treatment was attributed to the death of bulk tumor cells (CD133<sup>−</sup> cells), or CDDP treatment itself triggers CD133 expression. We discuss the results in the revised manuscript. CDDP treatment dramatically inhibited A549 cell viability in a dose-dependent manner. However, CD133<sup>+</sup> cancer stem cell proportions increased in the CDDP group, along with the enhanced expression of stemness markers, which is consistent with previous studies.<sup><xref rid="bibr13-1753466619866097" ref-type="bibr">13</xref>,<xref rid="bibr15-1753466619866097" ref-type="bibr">15</xref></sup> Therefore, chemotherapy such as CDDP treatment disappointingly leads to cancer stem cell enrichment, which may be the crucial reason for drug resistance.</p><p>Autophagy is necessary for various biological processes, including tumorigenesis and tumor development; however, the correlation between autophagy and cancer is still confused. The absence of autophagy leads to abnormal accumulations of destroyed organelles and biomacromolecules that further induce oxidative stress, DNA damage and other cellular damage, and finally cellular carcinogenesis.<sup><xref rid="bibr23-1753466619866097" ref-type="bibr">23</xref>,<xref rid="bibr24-1753466619866097" ref-type="bibr">24</xref></sup> Doxorubicin induced autophagy in wild-type cells, but not PARP-1 deficiency (<italic>parp-1-/-</italic>) or PARP inhibitor-treated cells. Absence of autophagy in <italic>parp-1-/-</italic> cells prevented ATP and NAD<sup>+</sup> depletion, indicating the protecting role of autophagy in DNA damage.<sup><xref rid="bibr25-1753466619866097" ref-type="bibr">25</xref></sup> Through attenuating metabolic stress and preventing necrosis-induced cell death, autophagy functions as a tumor suppressor in solid tumors.<sup><xref rid="bibr26-1753466619866097" ref-type="bibr">26</xref></sup> On the other hand, materials and energy after autophagy are essential for the highly proliferating tumor cells.<sup><xref rid="bibr17-1753466619866097" ref-type="bibr">17</xref></sup> The receptor for advanced glycation end products (RAGE) downregulation in pancreatic tumor cells decreased autophagy levels and suppressed tumor cell survival, indicating the positive correlation of autophagy and tumor cell survival in RAGE-mediated cell response to stress.<sup><xref rid="bibr27-1753466619866097" ref-type="bibr">27</xref></sup> Beclin1 deficiency-mediated autophagy impairment suppressed mammary cancer development in a PALB2 loss-associated hereditary breast cancer model,<sup><xref rid="bibr28-1753466619866097" ref-type="bibr">28</xref></sup> indicating autophagy accelerated mammary cancer growth. In our study, enriched CD133<sup>+</sup> A549 cancer stem cells displayed higher autophagy levels than CD133<sup>−</sup> A549 cells, indicating the correlation of autophagy with NSCLC cancer stem cells. Autophagy inhibition by CQ greatly suppressed CD133<sup>+</sup> cancer stem cells in sorted cells. The inhibition of CQ-mediated autophagy dramatically decreased the ability of colony formation and sphere formation of CD133<sup>+</sup> cancer stem cells. Therefore, autophagy levels are positively associated with the biological properties of NSCLC cancer stem cells.</p><p>Another important influence of autophagy on the effect of CDDP was determined based on the fact that increased autophagy levels enhanced drug resistance of CDDP-based chemotherapy in various types of cancer.<sup><xref rid="bibr18-1753466619866097" ref-type="bibr">18</xref>,<xref rid="bibr19-1753466619866097" ref-type="bibr">19</xref></sup> CDDP treatment promoted the autophagy of ovarian cancer cells by activating ERK signaling. ERK inhibition by MEK inhibitors or siRNA-mediated ERK downregulation suppressed autophagy and sensitized tumor cells to CDDP challenge. More importantly, in established CDDP-resistant tumor cells, autophagy inhibition enhanced CDDP-induced cell apoptosis.<sup><xref rid="bibr18-1753466619866097" ref-type="bibr">18</xref></sup> Disruption of autophagy by CQ dramatically enhanced the effect of suberanilohydroxamic acid in imatinib-resistant chronic myelogenous leukemia cells.<sup><xref rid="bibr29-1753466619866097" ref-type="bibr">29</xref></sup> Our results demonstrated that CDDP treatment alone showed no significant influence on cell viability of A549 cells, while a combination of CDDP and CQ-mediated autophagy inhibition significantly suppressed cell viability of A549 cells. In xenograft tumors, combination treatment displayed a more effective role in inhibiting tumor growth and tumor cell proliferation and promoting cell apoptosis. More importantly, CD133<sup>+</sup> cancer stem cells were significantly inhibited in tumor tissues.</p><p>It is important to note the limitations of this study. First, only one human NSCLC cell line (A549) was used in this study. It will be more convincing if we found similar results using another cell line. Second, the <italic>in vivo</italic> experiments were performed in NOD/SCID mice, which is somewhat limiting because of the inefficiency of the immune system. Spontaneous NSCLC mouse models or mouse NSCLC cell lines with injection into the same background mice would be a better choice to detect the effect of CDDP + CQ treatment. Third, the correlation between autophagy levels and clinical NSCLC progression may need better evidence to support the conclusion.</p><p>In summary, chemotherapy enhanced CD133<sup>+</sup> cells in clinical NSCLC specimens and NSCLC cell lines. The enriched CD133<sup>+</sup> cells exhibited higher autophagy levels. Autophagy inhibition by CQ inhibited CD133<sup>+</sup> cell stemness and promoted CDDP efficiency in A549 cells. More importantly, a combination of CDDP and CQ treatment significantly inhibited cancer stem cell proportions <italic>in vitro</italic>, and dramatically suppressed tumor growth <italic>in vivo</italic>. All the results indicated that autophagy inhibition of cancer stem cells promotes the efficacy of CDDP against NSCLC.</p></sec><sec sec-type="conclusions" id="section24-1753466619866097"><title>Conclusion</title><p>Autophagy inhibition of cancer stem cells promotes the efficacy of CDDP against NSCLC. Autophagy inhibition could serve as a promising strategy for NSCLC treatment.</p></sec><sec sec-type="supplementary-material" id="section25-1753466619866097" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl1-1753466619866097"><caption><title>Author_Response_1_(2) – Supplemental material for Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma</title></caption><media xlink:href="Author_Response_1_(2).pdf"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, Author_Response_1_(2) for Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma by Chengcheng Hao, Guiping Liu and Guangliang Tian in Therapeutic Advances in Respiratory Disease</p></supplementary-material></sec><sec sec-type="supplementary-material" id="section26-1753466619866097" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl2-1753466619866097"><caption><title>Reviewer_2_v.1_(1) – Supplemental material for Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma</title></caption><media xlink:href="Reviewer_2_v.pdf"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, Reviewer_2_v.1_(1) for Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma by Chengcheng Hao, Guiping Liu and Guangliang Tian in Therapeutic Advances in Respiratory Disease</p></supplementary-material></sec><sec sec-type="supplementary-material" id="section27-1753466619866097" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl3-1753466619866097"><caption><title>Supplemental_information – Supplemental material for Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma</title></caption><media xlink:href="Supplemental_information.pdf"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, Supplemental_information for Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma by Chengcheng Hao, Guiping Liu and Guangliang Tian in Therapeutic Advances in Respiratory Disease</p></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> The authors declare that there is no conflict of interest.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Guangliang Tian <inline-graphic xlink:href="10.1177_1753466619866097-img1.jpg"></inline-graphic><ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-9464-8307">https://orcid.org/0000-0001-9464-8307</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1753466619866097"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2017</article-title>. <source>CA Cancer J Clin</source><year>2017</year>; <volume>67</volume>: <fpage>7</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">28055103</pub-id></mixed-citation></ref><ref id="bibr2-1753466619866097"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source><year>2018</year>; <volume>68</volume>: <fpage>394</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation></ref><ref id="bibr3-1753466619866097"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zappa</surname><given-names>C</given-names></name><name><surname>Mousa</surname><given-names>SA.</given-names></name></person-group><article-title>Non-small cell lung cancer: current treatment and future advances</article-title>. <source>Transl Lung Cancer Res</source><year>2016</year>; <volume>5</volume>: <fpage>288</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">27413711</pub-id></mixed-citation></ref><ref id="bibr4-1753466619866097"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doroshow</surname><given-names>DB</given-names></name><name><surname>Herbst</surname><given-names>RS.</given-names></name></person-group><article-title>Treatment of advanced non-small cell lung cancer in 2018</article-title>. <source>JAMA Oncol</source><year>2018</year>; <volume>4</volume>: <fpage>569</fpage>–<lpage>570</lpage>.<pub-id pub-id-type="pmid">29494728</pub-id></mixed-citation></ref><ref id="bibr5-1753466619866097"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilz</surname><given-names>GP</given-names></name><name><surname>Becker</surname><given-names>H.</given-names></name></person-group><article-title>Antigen-antibody complexes: physiology and pathology</article-title>. <source>Wien Med Wochenschr Suppl</source><year>1990</year>; <volume>107</volume>: <fpage>2</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">1700869</pub-id></mixed-citation></ref><ref id="bibr6-1753466619866097"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelland</surname><given-names>L.</given-names></name></person-group><article-title>The resurgence of platinum-based cancer chemotherapy</article-title>. <source>Nat Rev Cancer</source><year>2007</year>; <volume>7</volume>: <fpage>573</fpage>–<lpage>584</lpage>.<pub-id pub-id-type="pmid">17625587</pub-id></mixed-citation></ref><ref id="bibr7-1753466619866097"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Harrington</surname><given-names>D</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name><etal>et al</etal></person-group><article-title>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><year>2002</year>; <volume>346</volume>: <fpage>92</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">11784875</pub-id></mixed-citation></ref><ref id="bibr8-1753466619866097"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Quintana</surname><given-names>E</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><etal>et al</etal></person-group><article-title>Heterogeneity in cancer: cancer stem cells versus clonal evolution</article-title>. <source>Cell</source><year>2009</year>; <volume>138</volume>: <fpage>822</fpage>–<lpage>829</lpage>.<pub-id pub-id-type="pmid">19737509</pub-id></mixed-citation></ref><ref id="bibr9-1753466619866097"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname><given-names>JE</given-names></name><name><surname>Lindeman</surname><given-names>GJ.</given-names></name></person-group><article-title>Cancer stem cells: current status and evolving complexities</article-title>. <source>Cell stem cell</source><year>2012</year>; <volume>10</volume>: <fpage>717</fpage>–<lpage>728</lpage>.<pub-id pub-id-type="pmid">22704512</pub-id></mixed-citation></ref><ref id="bibr10-1753466619866097"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottschling</surname><given-names>S</given-names></name><name><surname>Schnabel</surname><given-names>PA</given-names></name><name><surname>Herth</surname><given-names>FJ</given-names></name><etal>et al</etal></person-group><article-title>Are we missing the target? cancer stem cells and drug resistance in non-small cell lung cancer</article-title>. <source>Cancer Genomics Proteomics</source><year>2012</year>; <volume>9</volume>: <fpage>275</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">22990107</pub-id></mixed-citation></ref><ref id="bibr11-1753466619866097"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarvi</surname><given-names>S</given-names></name><name><surname>Mackinnon</surname><given-names>AC</given-names></name><name><surname>Avlonitis</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist</article-title>. <source>Cancer Res</source><year>2014</year>; <volume>74</volume>: <fpage>1554</fpage>–<lpage>1565</lpage>.<pub-id pub-id-type="pmid">24436149</pub-id></mixed-citation></ref><ref id="bibr12-1753466619866097"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akunuru</surname><given-names>S</given-names></name><name><surname>James Zhai</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name></person-group><article-title>Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity</article-title>. <source>Cell Death Dis</source><year>2012</year>; <volume>3</volume>: <fpage>e352</fpage>.<pub-id pub-id-type="pmid">22825470</pub-id></mixed-citation></ref><ref id="bibr13-1753466619866097"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YP</given-names></name><name><surname>Yang</surname><given-names>CJ</given-names></name><name><surname>Huang</surname><given-names>MS</given-names></name><etal>et al</etal></person-group><article-title>Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling</article-title>. <source>Cancer Res</source><year>2013</year>; <volume>73</volume>: <fpage>406</fpage>–<lpage>416</lpage>.<pub-id pub-id-type="pmid">23135908</pub-id></mixed-citation></ref><ref id="bibr14-1753466619866097"><label>14</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><etal>et al</etal></person-group><article-title>CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway</article-title>. <conf-name>Oncogene</conf-name><year>2008</year>; <volume>27</volume>: <fpage>1749</fpage>–<lpage>1758</lpage>.</mixed-citation></ref><ref id="bibr15-1753466619866097"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>G</given-names></name><name><surname>Roz</surname><given-names>L</given-names></name><name><surname>Perego</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment</article-title>. <source>Proc Natl Acad Sci USA</source><year>2009</year>; <volume>106</volume>: <fpage>16281</fpage>–<lpage>16286</lpage>.<pub-id pub-id-type="pmid">19805294</pub-id></mixed-citation></ref><ref id="bibr16-1753466619866097"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Komatsu</surname><given-names>M.</given-names></name></person-group><article-title>Autophagy: renovation of cells and tissues</article-title>. <source>Cell</source><year>2011</year>; <volume>147</volume>: <fpage>728</fpage>–<lpage>741</lpage>.<pub-id pub-id-type="pmid">22078875</pub-id></mixed-citation></ref><ref id="bibr17-1753466619866097"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JY</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>E.</given-names></name></person-group><article-title>Autophagy-mediated tumor promotion</article-title>. <source>Cell</source><year>2013</year>; <volume>155</volume>: <fpage>1216</fpage>–<lpage>1219</lpage>.<pub-id pub-id-type="pmid">24315093</pub-id></mixed-citation></ref><ref id="bibr18-1753466619866097"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>GS.</given-names></name></person-group><article-title>Role of autophagy in cisplatin resistance in ovarian cancer cells</article-title>. <source>J Biol Chem</source><year>2014</year>; <volume>289</volume>: <fpage>17163</fpage>–<lpage>17173</lpage>.<pub-id pub-id-type="pmid">24794870</pub-id></mixed-citation></ref><ref id="bibr19-1753466619866097"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Rehman</surname><given-names>SK</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>Autophagy is a therapeutic target in anticancer drug resistance</article-title>. <source>Biochim Biophys Acta</source><year>2010</year>; <volume>1806</volume>: <fpage>220</fpage>–<lpage>229</lpage>.<pub-id pub-id-type="pmid">20637264</pub-id></mixed-citation></ref><ref id="bibr20-1753466619866097"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Fojo</surname><given-names>T</given-names></name><name><surname>Bates</surname><given-names>S.</given-names></name></person-group><article-title>Tumour stem cells and drug resistance</article-title>. <source>Nat Rev Cancer</source><year>2005</year>; <volume>5</volume>: <fpage>275</fpage>–<lpage>284</lpage>.<pub-id pub-id-type="pmid">15803154</pub-id></mixed-citation></ref><ref id="bibr21-1753466619866097"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeppernick</surname><given-names>F</given-names></name><name><surname>Ahmadi</surname><given-names>R</given-names></name><name><surname>Campos</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Stem cell marker CD133 affects clinical outcome in glioma patients</article-title>. <source>Clin Cancer Res</source><year>2008</year>; <volume>14</volume>: <fpage>123</fpage>–<lpage>129</lpage>.<pub-id pub-id-type="pmid">18172261</pub-id></mixed-citation></ref><ref id="bibr22-1753466619866097"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N.</given-names></name></person-group><article-title>Methods for monitoring autophagy</article-title>. <source>Int J Biochem</source><year>2004</year>; <volume>36</volume>: <fpage>2491</fpage>–<lpage>2502</lpage>.</mixed-citation></ref><ref id="bibr23-1753466619866097"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>T</given-names></name><name><surname>Vanoli</surname><given-names>F</given-names></name><name><surname>Chiolo</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>HDACs link the DNA damage response, processing of double-strand breaks and autophagy</article-title>. <source>Nature</source><year>2011</year>; <volume>471</volume>: <fpage>74</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">21368826</pub-id></mixed-citation></ref><ref id="bibr24-1753466619866097"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>Autophagy fights disease through cellular self-digestion</article-title>. <source>Nature</source><year>2008</year>; <volume>451</volume>: <fpage>1069</fpage>–<lpage>1075</lpage>.<pub-id pub-id-type="pmid">18305538</pub-id></mixed-citation></ref><ref id="bibr25-1753466619866097"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Gamez</surname><given-names>JA</given-names></name><name><surname>Rodriguez-Vargas</surname><given-names>JM</given-names></name><name><surname>Quiles-Perez</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>PARP-1 is involved in autophagy induced by DNA damage</article-title>. <source>Autophagy</source><year>2009</year>; <volume>5</volume>: <fpage>61</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">19001878</pub-id></mixed-citation></ref><ref id="bibr26-1753466619866097"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degenhardt</surname><given-names>K</given-names></name><name><surname>Mathew</surname><given-names>R</given-names></name><name><surname>Beaudoin</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis</article-title>. <source>Cancer Cell</source><year>2006</year>; <volume>10</volume>: <fpage>51</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">16843265</pub-id></mixed-citation></ref><ref id="bibr27-1753466619866097"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Schapiro</surname><given-names>NE</given-names></name><etal>et al</etal></person-group><article-title>The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival</article-title>. <source>Cell Death Differ</source><year>2010</year>; <volume>17</volume>: 666–76.</mixed-citation></ref><ref id="bibr28-1753466619866097"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Teplova</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer</article-title>. <source>Cancer Discov</source><year>2013</year>; <volume>3</volume>: <fpage>894</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">23650262</pub-id></mixed-citation></ref><ref id="bibr29-1753466619866097"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Nawrocki</surname><given-names>ST</given-names></name><name><surname>Kahue</surname><given-names>CN</given-names></name><etal>et al</etal></person-group><article-title>Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance</article-title>. <source>Blood</source><year>2007</year>; <volume>110</volume>: <fpage>313</fpage>–<lpage>322</lpage>.<pub-id pub-id-type="pmid">17363733</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6676261
|texte= Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31368411" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |